{"cord_uid": "otf9ruvj", "sourcedb": "PMC", "sourceid": "PMC5827994", "divid": "18", "text": "A total of 57 patients with ARDS requiring ECMO therapy between 2013 and 2016 were analyzed retrospectively . Twenty - eight patients were treated with IgM - enriched immunoglobulins ( IVIG ) for 3 days according to the manufacturer ' s instruction ( IVIG group ) , and 29 patients did not receive IVIG therapy ( control group ) . No adverse events were reported after IVIG application . The median age of both groups was 52 years , ranging from 27 to 76 years in the control group and from 17 to 78 years in the IVIG group . The median Simplified Acute Physiology Score ( SAPS ) and Acute Physiology And Chronic Health Evaluation ( APACHE ) score were comparable between both groups ( Table 1 ) . The median APACHE score in the IVIG group was 24 vs . 23 in the control group . In 30 % ( 8 / 27 ) of the IVIGtreated patients and 31 % ( 9 / 29 ) of the control patients , the APACHE score was equal to or greater than 28 . Regarding preexisting disease , diabetes mellitus , cardiac disease , immune suppression , and malignancy were more common in the IVIG group ( Table 1 ) .", "project": "cdlai_CORD-19", "denotations": [{"id": "A-biobert_T1", "span": {"begin": 152, "end": 183}, "obj": "Gene"}, {"id": "A-biobert_T2", "span": {"begin": 633, "end": 640}, "obj": "Gene"}, {"id": "A-biobert_T3", "span": {"begin": 709, "end": 716}, "obj": "Gene"}, {"id": "A-biobert_T4", "span": {"begin": 875, "end": 882}, "obj": "Gene"}]}